Business Context and Reporting Period
This Form 8-K reports the results of the 2021 Annual Meeting of Stockholders for Rocket Pharmaceuticals, Inc., held on June 14, 2021. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol RCKT.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders representing approximately 88.92% of eligible shares (55,209,568 shares) participated in the meeting. The following proposals were approved:
- Election of Directors: All eight nominees were elected to the Board of Directors. Vote counts varied, with Elisabeth Björk, M.D., Ph.D. receiving the highest support (48,505,166 votes for) and Naveen Yalamanchi, M.D. receiving the lowest (34,245,562 votes for).
- Ratification of Auditors: Stockholders ratified the appointment of EisnerAmper LLP as the independent registered accounting firm for the fiscal year ending December 31, 2021, with 55,188,792 votes in favor.
- Executive Compensation (Say-on-Pay): Stockholders approved the non-binding advisory vote on executive compensation with 48,398,773 votes in favor.
- Frequency of Say-on-Pay Votes: Stockholders voted to conduct future advisory votes on executive compensation annually ("Each Year"), receiving 48,930,128 votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It is strictly a disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the tenure and background of the newly elected directors, particularly those with significant "Votes Withheld" (e.g., Naveen Yalamanchi, M.D., with 14,795,290 withheld votes).
- Confirm the engagement terms and scope of work for the newly ratified auditor, EisnerAmper LLP.
- Review the full Proxy Statement referenced in the filing for detailed executive compensation data and the rationale behind the "Say-on-Pay" vote.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial health metrics.